Anja Harmeier is an experienced drug developer, scientist and entrepreneur in neuroscience and rare diseases. She brings extensive R&D and operational capabilities complemented by a strong track record in company development and venture capital.
Anja joined Rewind from Pureos Bioventures where, as Partner, she was responsible for investments in innovative life sciences companies in the US and Europe including Vico Therapeutics, Corlieve Therapeutics (acquired by UniQure), and River Renal 2 and River Renal 3. Prior to Pureos, Anja held several positions at F. Hoffman-La Roche, initially joining the Neuroscience R&D group before working in positions of increasing seniority, including franchise and senior project leader in rare diseases. Starting in 2016, she served as an Investment Director at Roche Venture Fund, where she was on the Board of Directors at several of the fund’s portfolio companies, including Vivet Therapeutics (which Pfizer has an option to acquire), Entrada (IPO) and NMD Pharma.
Anja Harmeier holds a PhD in Neuroscience/ Biochemistry from the Institute of Biochemistry at Freie Universität Berlin and an MBA from Instituto de Empresa (ie) Madrid.